NSRX Schedule 13G: Megiddo reports 1,888,873 shares, 20.9%

Rhea-AI Filing Summary

Nasus Pharma Ltd. (NSRX) reported a significant shareholder on Schedule 13G. Dr. Dalia Megiddo beneficially owns 1,888,873 ordinary shares, representing 20.9% of the class. She holds sole voting and sole dispositive power over all reported shares.

The percentage is based on 9,014,105 ordinary shares outstanding as of September 30, 2025, as advised to the reporting person. The filing relates to ordinary shares (CUSIP M7071P109).

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Nasus Pharma Ltd.

(Name of Issuer)

Ordinary Shares

(Title of Class of Securities)

M7071P109

(CUSIP Number)

09/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. M7071P109

1

Names of Reporting Persons

Dr. Dalia Megiddo

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

ISRAEL

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,888,873.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,888,873.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,888,873.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

20.9 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: (1) Based on 9,014,105 ordinary shares that the issuer has advised the Reporting Person were issued and outstanding as of September 30, 2025.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Nasus Pharma Ltd.
(b)	Address of issuer's principal executive offices: Yigal Alon 65, Tel Aviv, 6744317, Israel.
Item 2.
(a)	Name of person filing: This Statement is filed on behalf of Dr. Dalia Megiddo.
(b)	Address or principal business office or, if none, residence: The address of the Reporting Persons is: c/o Nasus Pharma Ltd. Yigal Alon 65, Tel Aviv, 6744317, Israel
(c)	Citizenship: Dr. Dalia Megiddo is a citizen of the State of Israel.
(d)	Title of class of securities: Ordinary Shares
(e)	CUSIP No.: M7071P109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1,888,873 ordinary shares
(b)	Percent of class: 20.9%(1) (1) Based on 9,014,105 ordinary shares that the issuer has advised the Reporting Person were issued and outstanding as of September 30, 2025.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1,888,873
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 1,888,873
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dr. Dalia Megiddo

Signature:	/s/ Dalia Megiddo
Name/Title:	Dalia Megiddo
Date:	11/12/2025

FAQ

What did NSRX disclose in this Schedule 13G?

A significant ownership report stating Dr. Dalia Megiddo beneficially owns 1,888,873 Nasus Pharma ordinary shares.

What percentage of Nasus Pharma (NSRX) does Dr. Megiddo own?

She beneficially owns 20.9% of the ordinary shares.

How many shares are outstanding for NSRX used in this calculation?

The calculation is based on 9,014,105 ordinary shares outstanding as of September 30, 2025.

What voting and dispositive powers are reported?

She has sole voting power and sole dispositive power over 1,888,873 shares; 0 shared power.

What is the class of securities and CUSIP for NSRX in this filing?

Class: Ordinary Shares; CUSIP: M7071P109.

What is the date of the event requiring the filing?

The event date is 09/30/2025.

Who is the reporting person and their citizenship?

Reporting person: Dr. Dalia Megiddo, a citizen of Israel.